Prospera Financial Services Inc Has $4.93 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

Prospera Financial Services Inc lowered its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 38.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,766 shares of the biopharmaceutical company’s stock after selling 5,367 shares during the period. Prospera Financial Services Inc’s holdings in Regeneron Pharmaceuticals were worth $4,929,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of REGN. Brighton Jones LLC boosted its position in Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after acquiring an additional 686 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth approximately $226,000. Concurrent Investment Advisors LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 136.4% during the second quarter. Concurrent Investment Advisors LLC now owns 1,622 shares of the biopharmaceutical company’s stock worth $852,000 after purchasing an additional 936 shares during the period. MGO One Seven LLC increased its stake in Regeneron Pharmaceuticals by 28.1% in the 2nd quarter. MGO One Seven LLC now owns 483 shares of the biopharmaceutical company’s stock valued at $254,000 after buying an additional 106 shares during the period. Finally, Sequoia Financial Advisors LLC increased its stake in Regeneron Pharmaceuticals by 9.0% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 1,761 shares of the biopharmaceutical company’s stock valued at $925,000 after buying an additional 146 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Activity

In other news, SVP Jason Pitofsky sold 2,036 shares of the business’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $778.52, for a total value of $1,585,066.72. Following the completion of the sale, the senior vice president directly owned 4,272 shares in the company, valued at approximately $3,325,837.44. The trade was a 32.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bonnie L. Bassler sold 1,500 shares of the firm’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at $1,362,400. The trade was a 46.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,636 shares of company stock valued at $2,862,920 over the last 90 days. 7.02% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $778.97 on Thursday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $821.11. The stock’s 50-day moving average is $759.25 and its two-hundred day moving average is $662.51. The firm has a market cap of $81.87 billion, a P/E ratio of 18.74, a price-to-earnings-growth ratio of 2.03 and a beta of 0.40. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the prior year, the firm posted $12.07 EPS. The firm’s revenue for the quarter was up 2.5% on a year-over-year basis. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 5th. Shareholders of record on Friday, February 20th will be issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date is Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 8.47%.

Wall Street Analysts Forecast Growth

REGN has been the subject of a number of research reports. HSBC raised shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 24th. Evercore lifted their price objective on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a research report on Thursday, January 22nd. Bank of America raised Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and upped their target price for the stock from $627.00 to $860.00 in a research report on Wednesday, January 7th. Scotiabank raised their price target on Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a research note on Monday, November 24th. Finally, UBS Group boosted their price target on Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a research note on Friday, November 7th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $793.81.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.